Digitisation | November 05, 2021
CorporateServe launches PharmaSoft 2.0
The solution helps the pharma enterprises drive efficiencies, save costs, and increase productivity
The solution helps the pharma enterprises drive efficiencies, save costs, and increase productivity
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
